866-997-4948(US-Canada Toll Free)

Hyperuricemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Nov 2013

Category :

Metabolic Disorders

No. of Pages : 51 Pages


Global Markets Directs, \'Hyperuricemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperuricemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperuricemia. Hyperuricemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hyperuricemia.
  • A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hyperuricemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hyperuricemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperuricemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Hyperuricemia 8
Hyperuricemia Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Hyperuricemia Therapeutics - Products under Development by Companies 15
Companies Involved in Hyperuricemia Therapeutics Development 16
AstraZeneca PLC 16
Teijin Pharma Limited 17
Chugai Pharmaceutical Co. Ltd 18
Kissei Pharmaceutical Co., Ltd. 19
Nippon Chemiphar Co., Ltd. 20
Polaris Group 21
Hyperuricemia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
lesinurad - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
arhalofenate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Uricase-PEG 20 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
febuxostat - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
KUX-1151 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NC-2500 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KGO-2142 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KGO-2173 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
JPH-367 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
UR-1102 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Hyperuricemia Therapeutics - Drug Profile Updates 41
Hyperuricemia Therapeutics - Discontinued Products 43
Hyperuricemia Therapeutics - Dormant Products 44
Hyperuricemia - Product Development Milestones 45
Featured News & Press Releases 45
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 45
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 45
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 46
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 46
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 47
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 47
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 48
Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada 48
Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe 49
Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout 49

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Table


Number of Products Under Development for Hyperuricemia, H2 2013 8
Products under Development for Hyperuricemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
AstraZeneca PLC, H2 2013 16
Teijin Pharma Limited, H2 2013 17
Chugai Pharmaceutical Co. Ltd, H2 2013 18
Kissei Pharmaceutical Co., Ltd., H2 2013 19
Nippon Chemiphar Co., Ltd., H2 2013 20
Polaris Group, H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Hyperuricemia Therapeutics - Drug Profile Updates 41
Hyperuricemia Therapeutics - Discontinued Products 43
Hyperuricemia Therapeutics - Dormant Products 44

List of Chart


Number of Products under Development for Hyperuricemia, H2 2013 8
Products under Development for Hyperuricemia - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *